PBforum

HCIL reported a revenue growth of 11% QoQ to Rs 2842 mn on the back of 7% QoQ increase in sales volumes to 0.80 mt & 3% improvement in realisations to Rs 3557/tn.

The Standalone for Q4FY12 stood at Rs42bn down 25% y-o-y led by a major fall in the Energy segment by 39% and the Environment segment by 7%. Order inflows for FY12 stood at Rs40bn down by 35%.

Cummins India reported a flat top-line YoY of Rs10.4bn (sales break-up: 34% PowerGen, 13% IBU, 4% Auto, 17% Distribution and 32% Exports).

The consolidated net sales of Marico increased by 22.9% to Rs9177.1 mn with a robust volume growth of 17%. Organic volume growth stood at 13%.

Unitech's Q4FY12 numbers has been impacted by severe cost overrun (prior period adjustment done in 4QFY12). Core real estate EBIT margin was 17% as against 27-30% in 9MFY12. MTM loss provisioning relating to dollar-linked investment further impacted profitability

During the quarter, Shree Cement's revenues grew 38% y-o-y (+17% q-o-q) to Rs14.8b (v/s est Rs15.3b); EBITDA margin was down 250bp y-o-y (+120bp q-o-q) at 25.2% (v/s est 26.7%). Higher other income and lower depreciation further boosted adj. PAT to Rs1.16b (v/s est Rs972m)

After making an all time high at Rs887 Bata India is making 'Lower Top Lower Bottom' formation for last 10 trading sessions.

L&T reported revenue growth of 21% y-o-y and EBITDA growth of 9% y-o-y for Q4FY12, largely in line with estimates. PAT grew 22% y-o-y, higher than the estimate, supported by higher other income, lower interest and lower tax rates. Maintain buy for a price target of Rs1417

SPA are positive on long term growth opportunities for the rating business in India and believe ICRA is strongly positioned to take advantage of growth in debt market in India which is currently at nascent stage.

MBECL reported steady set of numbers on standalone basis in Q4FY12, with both topline and bottomline surpassing expectations led by strong revenue bookings. The company has registered a standalone topline growth of 5% y-o-y (+48% q-o-q) to Rs7258 mn, while its bottomline has remained flat at Rs224 mn, due to sharp increase in interest expenses

During the quarter, the company's consolidated net sales grew by 30.9% to Rs13230.4 mn. Indian subcontinent business grew by 21% led by healthy growth across the core categories especially soaps & household insecticides. PAT margins expanded by 55 bps y-o-y to 14.6%. Buy at CMP and average on dips

Lupin has received approval and subsequently launched generic Lamivudine and Zidovudine Tablets in the US. Nirmal Bang anticipated the launch, and had factored in USD22mn revenue from this product in FY13.

Pantaloon's Q3FY12 performance indicates continued stress in its core retail business. Prabhudas Lilladher is not rolling forward to FY14e in PF as they await more details on business composition post the ABNUVO-PF deal.

Nirmal Bang expects SBI to report profit growth, asset quality issues would take precedence over the reported earnings as weaker macro-environment and higher delinquencies would taper down growth moving ahead.